RxDoctor Payments Data

Manika Zeri, MD

Internal Medicine · Charlotte, NCNPI 1477757227

Payments from drug & device makers

$911in general payments, 2019–2025

Across 21 payments — averaging $43.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$641
  • Innovation Technologies Inc$109
  • Cardinal Health 110 LLC$100
  • Bristol Myers Squibb$23
  • AbbVie$22
  • GSK$16

What the payments were for

  • Consulting fees$10011%
  • Food & beverage$81189%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)16$641
Innovation Technologies Inc1$109
Cardinal Health 110 LLC1$100
Bristol Myers Squibb1$23
AbbVie1$22
GSK1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$911 in reported general payments places this provider in the 70th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,308,831
Medicare patients
312
Services billed
43,535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab34$326,181
RinvoqUpadacitinib20$193,500
Enbrel SureclickEtanercept12$85,718
Orencia ClickjectAbatacept13$74,418
OrenciaAbatacept11$62,969
OlumiantBaricitinib12$31,387
Actemra ActpenTocilizumab13$31,152
Hydroxychloroquine Sulfate215$8,830
MethotrexateMethotrexate Sodium235$5,049
Mycophenolate Mofetil34$3,431
Leflunomide40$3,210
Prednisone210$1,450
Celecoxib26$801
Azathioprine24$773
Methylprednisolone20$410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$22$193,50020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →